Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (452)	1/1/1999 7:32:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 645

CNBC just did a Biotech review with David Molowa from Bear Stearns and Michael Weinstein from JP Morgan. Ligand was mentioned by David Molowa. Expects ONTAK and Panretin approval "in the not too distant future" to make LGND proftable in 2nd half of this year. Peak of the two markets is $50 million per year each. Money will allow second wave of products next year. At end he also mentioned Vaccine Development and AVIR. These were the only two true Biotechs mentioned in a fairly long segment.